NEOLEUKIN THERAPEUTICS INC (NLTX) Stock Price, Quote, News and Overview
NASDAQ:NLTX - Nasdaq - US64049K2033 - Common Stock - Currency: USD
NLTX Quote, Performance and Key Statistics
3.49
+0.05 (+1.45%)
The current stock price of NLTX is 3.49 USD. In the past month the price increased by 4.18%. In the past year, price increased by 61.39%.
NLTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About NLTX
Company Profile
Neoleukin Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The firm is engaged in providing immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. The firm uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Its primarily focused on cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. The firm operates through the research and development of de novo protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. The firm's primary areas of focus are on oncology, inflammation, and autoimmunity. Its de novo protein design process uses a set of advanced computational algorithms and methods to design functional de novo proteins.
Company Info
NEOLEUKIN THERAPEUTICS INC
1616 Eastlake Ave E Ste 360
Seattle WASHINGTON 98102 US
CEO: Jonathan G. Drachman
Employees: 7
Company Website: https://www.neoleukin.com/
Phone: 12067322133
NEOLEUKIN THERAPEUTICS INC / NLTX FAQ
What is the stock price of NEOLEUKIN THERAPEUTICS INC today?
The current stock price of NLTX is 3.49 USD. The price increased by 1.45% in the last trading session.
What is the ticker symbol for NEOLEUKIN THERAPEUTICS INC stock?
The exchange symbol of NEOLEUKIN THERAPEUTICS INC is NLTX and it is listed on the Nasdaq exchange.
On which exchange is NLTX stock listed?
NLTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEOLEUKIN THERAPEUTICS INC stock?
6 analysts have analysed NLTX and the average price target is 1.53 USD. This implies a price decrease of -56.16% is expected in the next year compared to the current price of 3.49. Check the NEOLEUKIN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEOLEUKIN THERAPEUTICS INC worth?
NEOLEUKIN THERAPEUTICS INC (NLTX) has a market capitalization of 30.71M USD. This makes NLTX a Nano Cap stock.
How many employees does NEOLEUKIN THERAPEUTICS INC have?
NEOLEUKIN THERAPEUTICS INC (NLTX) currently has 7 employees.
What are the support and resistance levels for NEOLEUKIN THERAPEUTICS INC (NLTX) stock?
NEOLEUKIN THERAPEUTICS INC (NLTX) has a support level at 3.47 and a resistance level at 3.53. Check the full technical report for a detailed analysis of NLTX support and resistance levels.
Should I buy NEOLEUKIN THERAPEUTICS INC (NLTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NLTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NLTX, evaluating the profitability, health, valuation and growth aspects
- NEOLEUKIN THERAPEUTICS INC (NLTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEOLEUKIN THERAPEUTICS INC (NLTX) Sales and EPS estimates to see what analysts future expectations are.
- NEOLEUKIN THERAPEUTICS INC (NLTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEOLEUKIN THERAPEUTICS INC (NLTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEOLEUKIN THERAPEUTICS INC (NLTX) Stock Chart to make your own analysis
- NEOLEUKIN THERAPEUTICS INC (NLTX) Latest news and press-releases to stay up to date.
Does NEOLEUKIN THERAPEUTICS INC (NLTX) stock pay dividends?
NLTX does not pay a dividend.
When does NEOLEUKIN THERAPEUTICS INC (NLTX) report earnings?
NEOLEUKIN THERAPEUTICS INC (NLTX) will report earnings on 2024-03-18, after the market close.
What is the Price/Earnings (PE) ratio of NEOLEUKIN THERAPEUTICS INC (NLTX)?
NEOLEUKIN THERAPEUTICS INC (NLTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.2).
NLTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NLTX. When comparing the yearly performance of all stocks, NLTX is one of the better performing stocks in the market, outperforming 87.21% of all stocks.
NLTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NLTX. No worries on liquidiy or solvency for NLTX as it has an excellent financial health rating, but there are worries on the profitability.
NLTX Financial Highlights
Over the last trailing twelve months NLTX reported a non-GAAP Earnings per Share(EPS) of -5.2. The EPS decreased by -136.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.25% | ||
| ROE | -45.57% | ||
| Debt/Equity | 0 |
NLTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to NLTX. The Buy consensus is the average rating of analysts ratings from 6 analysts.